Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasm Metastasis 30Prostatic Neoplasms 18Lung Neoplasms 17Breast Neoplasms 17Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 14Pancreatic Neoplasms 13Multiple Myeloma 12Glioma 12Brain Neoplasms 11Carcinoma, Renal Cell 10Squamous Cell Carcinoma of Head and Neck 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Astrocytoma 9Neoplasms 8Melanoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Lymphoma, Non-Hodgkin 7Cholangiocarcinoma 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Gliosarcoma 6Central Nervous System Neoplasms 6Carcinoma 6

Interventions

Doxorubicin 3pembrolizumab 2Radiotherapy 2ribociclib 1peposertib 1montanide ISA 51 1liposomal doxorubicin 1itacitinib 1futibatinib 1cixutumumab 1belinostat 1baricitinib 1avelumab 1Specimen Handling 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Ifosfamide 1INCB039110 1Histamine H2 Antagonists 1Fluorouracil 1Famotidine 1Erlotinib Hydrochloride 1Chemotherapy, Adjuvant 1Celecoxib 1Biopsy 1BO-112 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Histiocytoma, Malignant Fibrous × Magnetic Resonance Spectroscopy × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡